lomustine has been researched along with Leukocytopenia in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 9.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)." | 9.05 | Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985) |
| "Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine." | 7.66 | Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 5.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)." | 5.05 | Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985) |
| "Sixty-four patients who received at least one cycle of a nitrosourea agent (nimustine or lomustine) and teniposide for recurrent glioma between 2008 and 2012; of these patients, 28 did not receive prophylactic pegfilgrastim (cohort A), and 36 patients received prophylactic pegfilgrastim (cohort B)." | 3.80 | Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma. ( Atta, J; Franz, K; Lemercier, S; Rieger, J; Steinbach, JP; Sulzbacher, A; Thiepold, AL, 2014) |
| "Nineteen patients with advanced non-Hodgkin's lymphoma resistant to previous chemotherapy were treated with combination chemotherapy consisting of lomustine (CCNU), cytarabine, and prednisone." | 3.66 | Salvage chemotherapy for non-Hodgkin's lymphoma. ( Khoo, RK; Ng, PR; Todd, D, 1982) |
| "Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine." | 3.66 | Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980) |
| "To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU." | 2.74 | High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. ( Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C, 2009) |
| "Thirty-five patients with advanced breast cancer refractory to initial chemotherapy were randomized to receive two-drug doxorubicin-CCNU or three-drug doxorubicin-CCNU-vincristine (VCR) treatment." | 2.65 | Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial. ( Bateman, JR; Block, JB; Chlebowski, RT; Pugh, R; Weiner, JM, 1983) |
| " The dosage of CCNU was 100 mg/m2 p." | 2.65 | The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981) |
| "It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men." | 2.64 | Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976) |
| "Thirty-two patients with recurrent Hodgkin's disease have been treated with an oral regimen employing lomustine (CCNU, 100 mg/m2 orally on Day 1); etoposide (VP-16, 100 mg/m2 orally on Days 1-3 and 21-23); and methotrexate (30 mg/m2 orally on Days 1, 8, 21, and 28)." | 1.27 | Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. ( Coleman, CN; Horning, SJ; Jacobs, C; Lewis, BJ; Rosenberg, SA; Tseng, A, 1987) |
| "One patient with Hodgkin's disease involving the liver is alive at 36 months with further therapy." | 1.26 | Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. ( Gamble, JF; Loh, KK; Rodgers, RW; Shullenberger, CC, 1980) |
| " The treatment dosage was 130 mg/m2 for patients with adequate bone marrow reserve and 100 mg/m2 for those with compromised bone marrow." | 1.26 | Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up. ( Armstrong, DM; Aust, JB; Cruz, AB; Fletcher, WS; Metter, G; Richardson, JD; Wilson, WL, 1976) |
| " In the first phase, 14 patients (Group A) with progressive neurologic dysfunction following primary treatment were treated with DTIC alone (8 patients) or in combination with CCNU or methyl CCNU (6 patients) and evaluated for change in neurologic status." | 1.25 | Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). ( Baxter, D; Cunningham, TJ; Horton, J; Nelson, L; Olson, KB; Rosenbaum, C; Sponzo, RW; Taylor, SG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (85.29) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 2 (5.88) | 29.6817 |
| 2010's | 1 (2.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thiepold, AL | 1 |
| Lemercier, S | 1 |
| Franz, K | 1 |
| Atta, J | 1 |
| Sulzbacher, A | 1 |
| Steinbach, JP | 1 |
| Rieger, J | 1 |
| Illerhaus, G | 1 |
| Marks, R | 1 |
| Müller, F | 1 |
| Ihorst, G | 1 |
| Feuerhake, F | 1 |
| Deckert, M | 1 |
| Ostertag, C | 1 |
| Finke, J | 1 |
| Zander, T | 1 |
| Nettekoven, W | 1 |
| Kraus, JA | 1 |
| Pels, H | 1 |
| Ko, YD | 1 |
| Vetter, H | 1 |
| Klockgether, T | 1 |
| Schlegel, U | 1 |
| Rodgers, RW | 1 |
| Gamble, JF | 1 |
| Loh, KK | 1 |
| Shullenberger, CC | 1 |
| Aisner, J | 1 |
| Whitacre, M | 1 |
| Van Echo, DA | 1 |
| Wiernik, PH | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 1 |
| Bernardo, G | 1 |
| Knerich, R | 1 |
| Butti, G | 1 |
| Cuzzoni, Q | 1 |
| Wilson, HE | 1 |
| Stanley, K | 1 |
| Vincent, RG | 1 |
| Mountain, CF | 1 |
| Sealy, R | 2 |
| Cohen, M | 1 |
| Chen, TY | 1 |
| Batley, F | 1 |
| Kilman, J | 1 |
| Kakos, G | 1 |
| Vasko, J | 1 |
| Williams, TE | 1 |
| Tucker, RD | 2 |
| Chlebowski, RT | 1 |
| Pugh, R | 1 |
| Weiner, JM | 1 |
| Block, JB | 1 |
| Bateman, JR | 2 |
| Chahinian, AP | 2 |
| Green, G | 1 |
| Holland, JF | 4 |
| Hansen, HH | 3 |
| Dombernowsky, P | 1 |
| Hirsch, FR | 1 |
| Hansen, M | 1 |
| Rygård, J | 1 |
| Selawry, OS | 2 |
| Pajak, TF | 3 |
| Spurr, CL | 1 |
| Falkson, G | 1 |
| Brunner, K | 2 |
| Cuttner, J | 2 |
| Nissen, NI | 2 |
| Cornwell, GG | 1 |
| Kochwa, S | 1 |
| McIntyre, OR | 1 |
| Glowienka, LP | 1 |
| Rafla, S | 1 |
| Silver, RT | 2 |
| Cooper, MR | 1 |
| Henderson, E | 1 |
| Kyle, RA | 1 |
| Haurani, FI | 1 |
| Ng, PR | 1 |
| Todd, D | 1 |
| Khoo, RK | 1 |
| Gagliano, RG | 1 |
| Panettiere, FJ | 1 |
| Haas, CD | 1 |
| Baker, L | 1 |
| Hewlett, J | 1 |
| Stuckey, WJ | 1 |
| O'Bryan, RM | 1 |
| Bottomley, R | 1 |
| Heilburn, LK | 1 |
| Carmo-Pereira, J | 1 |
| Costa, FO | 1 |
| Pimentel, P | 1 |
| Henriques, E | 1 |
| Gershanovich, ML | 1 |
| Akimov, MA | 1 |
| Hildebrand, J | 1 |
| Gangji, D | 1 |
| Nouwynck, C | 1 |
| Machin, D | 1 |
| Zeltzer, PM | 1 |
| Feig, SA | 1 |
| Taylor, SG | 1 |
| Nelson, L | 1 |
| Baxter, D | 1 |
| Rosenbaum, C | 1 |
| Sponzo, RW | 1 |
| Cunningham, TJ | 1 |
| Olson, KB | 1 |
| Horton, J | 1 |
| Stolinsky, DC | 1 |
| Bull, FE | 1 |
| Simon, R | 2 |
| Carr, DT | 1 |
| van Wyk, CE | 1 |
| Mandel, EM | 1 |
| Jaffrey, IS | 1 |
| Teirstein, AS | 1 |
| Maurice, P | 1 |
| Glidewell, O | 1 |
| Jacquillat, C | 1 |
| Carey, R | 1 |
| Pas, AT | 1 |
| Cornell, CJ | 1 |
| Burningham, RA | 1 |
| Alberto, P | 1 |
| Barrelet, L | 1 |
| Chapuis, B | 1 |
| Garcia, B | 1 |
| Johnson, RO | 1 |
| Metter, G | 2 |
| Wilson, W | 1 |
| Hill, G | 1 |
| Krementz, E | 1 |
| Cedermark, BJ | 1 |
| Didolkar, MS | 1 |
| Elias, EG | 1 |
| Wilson, WL | 2 |
| Andrews, NC | 1 |
| Frelick, RW | 1 |
| Nealon, TF | 1 |
| Bick, RL | 1 |
| Adams, T | 1 |
| Tejada, F | 1 |
| Eisenberger, MA | 1 |
| Broder, LA | 1 |
| Cohen, MH | 1 |
| Cruz, AB | 1 |
| Armstrong, DM | 1 |
| Aust, JB | 1 |
| Fletcher, WS | 1 |
| Richardson, JD | 1 |
| Gridelli, C | 1 |
| Contegiacomo, A | 1 |
| Lauria, R | 1 |
| Gentile, M | 1 |
| Airoma, G | 1 |
| De Placido, S | 1 |
| Perrone, F | 1 |
| Ferrante, G | 1 |
| Bianco, AR | 1 |
| Lahouel, M | 1 |
| Viotte, G | 1 |
| Sumereau, E | 1 |
| Morin, JP | 1 |
| Fillastre, JP | 1 |
| Tseng, A | 1 |
| Jacobs, C | 1 |
| Coleman, CN | 1 |
| Horning, SJ | 1 |
| Lewis, BJ | 1 |
| Rosenberg, SA | 1 |
| Bajetta, E | 1 |
| Buzzoni, R | 1 |
| Viviani, S | 1 |
| Vaglini, M | 1 |
| Nava, M | 1 |
| Bonadonna, G | 1 |
| Hess, WA | 1 |
| Kornblith, PL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy[NCT00989352] | Phase 2 | 56 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 trials available for lomustine and Leukocytopenia
| Article | Year |
|---|---|
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Comb | 2009 |
Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxoru | 1982 |
Comparison of chemotherapy alone versus chemotherapy and radiation therapy of extensive small cell carcinoma of the lung.
Topics: Aged; Body Weight; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, | 1983 |
Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial.
Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Humans; | 1983 |
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Bronchogenic; Clinical Trials as Top | 1980 |
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S | 1981 |
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1982 |
Enhancement of bone marrow toxicity of VM-26-CCNU combination by bleomycin.
Topics: Adult; Aged; Bleomycin; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combin | 1977 |
Combination chemotherapy of advanced lung cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; | 1976 |
Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma.
Topics: Clinical Trials as Topic; Female; Hodgkin Disease; Humans; Leukopenia; Lomustine; Lymphoma, Non-Hodg | 1978 |
A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Thera | 1975 |
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal | 1976 |
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms; | 1976 |
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
Topics: Adult; Aged; Altretamine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Eval | 1976 |
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea | 1977 |
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic | 1985 |
17 other studies available for lomustine and Leukocytopenia
| Article | Year |
|---|---|
Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Disease-Free Sur | 2014 |
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female | 2002 |
Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Dacarbazine; Doxorubicin; Drug Administra | 1980 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Salvage chemotherapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Lymphoma; | 1982 |
Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Colonic Neoplasms; Deoxyguanosine; Drug Evaluation; Drug Therapy, Combination; Human | 1981 |
Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged; | 1980 |
[Evaluation of the CCNU-COP regimen for primary refractory and recurrent non-Hodgkin's lymphoma].
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 1999 |
Theophylline-induced lomustine toxicity.
Topics: Drug Synergism; Female; Humans; Leukopenia; Lomustine; Middle Aged; Nitrosourea Compounds; Theophyll | 1979 |
Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441).
Topics: Adult; Brain Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Glioblastom | 1975 |
Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Bronchogenic; Carcinoma, Small Cell; | 1975 |
MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; | 1979 |
Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up.
Topics: Humans; Leukopenia; Lomustine; Neoplasms; Nitrosourea Compounds; Thrombocytopenia | 1976 |
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclo | 1991 |
Haematotoxicity of doxorubicin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and of their association in rats.
Topics: Animals; Blood Cell Count; Body Weight; Creatinine; Doxorubicin; Female; Hemoglobins; Leukopenia; Lo | 1987 |
Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocol | 1987 |
Combination of lomustine and cimetidine in the treatment of a patient with malignant glioblastoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Humans; Leukopenia; Lomustine; Male; Mid | 1985 |